Richmond Pharmacology is excited to join the AGAH Conference 2026 in Frankfurt, Germany, on 25- 26 February 2026.

Bringing together experts in clinical pharmacology and early-phase drug development, this conference is a key platform for advancing methodologies, regulatory strategies, and innovation in human pharmacology.

Representing Richmond Pharmacology:

  • Dr Jörg Taubel, Chief Executive Officer and President at AGAH
  • Dr Lisa Campbell, Director of Regulatory Strategy
  • James Rickard, Chief Scientific Officer (Richmond Research Institute)
  • Elizabeth Romano, Director of Communications and Participant Engagement

We look forward to connecting with attendees to discuss Richmond’s expertise in:

  • Innovations in early-phase trial design and execution
  • Regulatory frameworks for first-in-human studies
  • Biomarker-driven approaches to accelerate development
  • Patient-centric strategies in early-phase research
  • Collaboration between academia, industry, and regulators

Connect With Us

If you are attending AGAH Conference 2026 and would like to explore partnership or development opportunities email us at:

📧 fasteranswers@richmondpharmacology.com

Latest news

How Richmond Pharmacology Supports Sponsors Navigating ICH E6 (R3)

February 5, 2026
The updated ICH E6 (R3) guideline places greater emphasis on proportionality, risk-based oversight...
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event